Harris Jamie, Herrero-Garcia Erika, Russo Angela, Kajdacsy-Balla Andre, O'Bryan John P, Chiu Bill
*Department of Surgery, Rush University Medical Center †Department of Pharmacology, College of Medicine, University of Illinois at Chicago ‡Jesse Brown VA Medical Center Departments of § Pathology ¶Surgery, University of Illinois at Chicago ∥University of Illinois Cancer Center, University of Illinois at Chicago, Chicago, IL.
J Pediatr Hematol Oncol. 2017 Nov;39(8):e413-e418. doi: 10.1097/MPH.0000000000000931.
Neuroblastoma accounts for 15% of all pediatric cancer deaths. Intersectin 1 (ITSN1), a scaffold protein involved in phosphoinositide 3-kinase (PI3K) signaling, regulates neuroblastoma cells independent of MYCN status. We hypothesize that by silencing ITSN1 in neuroblastoma cells, tumor growth will be decreased in an orthotopic mouse tumor model. SK-N-AS neuroblastoma cells transfected with empty vector (pSR), vectors expressing scrambled shRNA (pSCR), or shRNAs targeting ITSN1 (sh#1 and sh#2) were used to create orthotopic neuroblastoma tumors in mice. Volume was monitored weekly with ultrasound. End-point was tumor volume >1000 mm. Tumor cell lysates were analyzed with anti-ITSN1 antibody by Western blot. Orthotopic tumors were created in all cell lines. Twenty-five days post injection, pSR tumor size was 917.6±247.7 mm, pSCR was 1180±159.9 mm, sh#1 was 526.3±212.8 mm, and sh#2 was 589.2±74.91 mm. sh#1-tumors and sh#2-tumors were smaller than pSCR (P=0.02), no difference between sh#1 and sh#2. Survival was superior in sh#2-tumors (P=0.02), trended towards improved survival in sh#1-tumors (P=0.09), compared with pSCR-tumors, no difference in pSR tumors. Western blot showed decreased ITSN1 expression in sh#1 and sh#2 compared with pSR and pSCR. Silencing ITSN1 in neuroblastoma cells led to decreased tumor growth in an orthotopic mouse model. Orthotopic animal models can provide insight into the role of ITSN1 pathways in neuroblastoma tumorigenesis.
神经母细胞瘤占所有儿童癌症死亡病例的15%。Intersectin 1(ITSN1)是一种参与磷酸肌醇3激酶(PI3K)信号传导的支架蛋白,可独立于MYCN状态调节神经母细胞瘤细胞。我们假设,通过沉默神经母细胞瘤细胞中的ITSN1,原位小鼠肿瘤模型中的肿瘤生长将会减缓。用空载体(pSR)、表达乱序短发夹RNA(pSCR)的载体或靶向ITSN1的短发夹RNA(sh#1和sh#2)转染的SK-N-AS神经母细胞瘤细胞,被用于在小鼠体内创建原位神经母细胞瘤肿瘤。每周用超声监测肿瘤体积。终点为肿瘤体积>1000立方毫米。通过蛋白质免疫印迹法,用抗ITSN1抗体分析肿瘤细胞裂解物。所有细胞系均成功创建原位肿瘤。注射后25天,pSR组肿瘤大小为917.6±247.7立方毫米,pSCR组为1180±159.9立方毫米,sh#1组为526.3±212.8立方毫米,sh#2组为589.2±74.91立方毫米。sh#1组和sh#2组的肿瘤小于pSCR组(P=0.02),sh#1组和sh#2组之间无差异。sh#2组的生存期更长(P=0.02),sh#1组的生存期有改善趋势(P=0.09),与pSCR组相比,pSR组无差异。蛋白质免疫印迹显示,与pSR组和pSCR组相比,sh#1组和sh#2组中ITSN-1表达降低。在原位小鼠模型中,沉默神经母细胞瘤细胞中的ITSN1可导致肿瘤生长减缓。原位动物模型有助于深入了解ITSN1通路在神经母细胞瘤肿瘤发生中的作用。